← Apogee Therapeutics, Inc. Common Stock overview
Apogee Therapeutics, Inc. Common StockAPGE

Why is Apogee Therapeutics, Inc. Common Stock (APGE) moving?

Q3 2026
▲3

AbbVie completes $10.9B Apogee buyout at $135.11 per share

  • AbbVie completes acquisition AbbVie finished buying Apogee for $135.11 per share in cash, a 49.5% premium. The deal closed by early October 2026, locking in the payout for Apogee shareholders.

    This is the final event that determined Apogee's value in Q3.

  • Debt-funded deal keeps AbbVie dividend safe AbbVie used debt to pay for the purchase, so its dividend remained safe and financing risk stayed low. This made the cash offer more certain for Apogee shareholders.

    It explains why the deal closed smoothly and the payout was reliable.

  • Baron Capital exit confirms final value Baron Capital sold its Apogee stake at the deal price, signaling that $135.11 is the final value. No higher bid emerged, so the cash offer stood as the best outcome.

    It shows the market accepted the deal price as final, removing uncertainty.

  • Fairness investigation adds minor uncertainty Halper Sadeh LLC investigated whether the $135.11 price was fair to Apogee shareholders. Such reviews rarely block deals, but they introduced slight uncertainty before closing.

    It is a real counterweight that could have delayed or altered the payout.

August 2026
▲3

AbbVie completes $10.9B Apogee buyout at $135.11 cash per share

  • AbbVie closes Apogee acquisition AbbVie completed its $10.9 billion purchase of Apogee, paying $135.11 in cash for each share. That locks in a 49.5% premium over Apogee's price before the deal was announced, so shareholders get a fixed cash payout rather than riding the stock market.

    The completed buyout is the single event that now determines what APGE holders receive, making it the core answer to why the stock moves.

  • Deal premium confirmed by big investor exit Baron Capital sold its Apogee stake after the buyout news, citing the $135.11 per-share offer as a 49.5% premium. When a long-term fund exits at the deal price, it signals the market treats the cash offer as the final value for Apogee shares.

    It shows professional investors accepting the buyout price as the realized value, reinforcing the positive floor under APGE.

  • Law firm probes deal fairness Halper Sadeh LLC is investigating whether Apogee's $135.11 per-share sale to AbbVie is fair to shareholders. Such reviews are common and rarely block a deal, but they can delay closing or pressure for a higher price, adding a small amount of uncertainty.

    It is the main counterweight to the buyout, showing the deal is not entirely risk-free for shareholders.

  • AbbVie's strong results support deal closing AbbVie reported 10.2% revenue growth and raised its profit outlook, while noting the Apogee purchase will slightly reduce its 2026 earnings. A healthy buyer with growing cash flow makes it more likely the all-cash deal closes on the agreed terms.

    AbbVie's financial strength is the practical backing for the $135.11 cash payment Apogee holders expect.

Latest
▲3

AbbVie completes $10.9B Apogee buyout at $135.11 cash per share

  • AbbVie closes Apogee acquisition AbbVie completed its $10.9 billion purchase of Apogee, paying $135.11 in cash for each share. That locks in a 49.5% premium over Apogee's price before the deal was announced, so shareholders get a fixed cash payout rather than riding the stock market.

    The completed buyout is the single event that now determines what APGE holders receive, making it the core answer to why the stock moves.

  • Deal premium confirmed by big investor exit Baron Capital sold its Apogee stake after the buyout news, citing the $135.11 per-share offer as a 49.5% premium. When a long-term fund exits at the deal price, it signals the market treats the cash offer as the final value for Apogee shares.

    It shows professional investors accepting the buyout price as the realized value, reinforcing the positive floor under APGE.

  • Law firm probes deal fairness Halper Sadeh LLC is investigating whether Apogee's $135.11 per-share sale to AbbVie is fair to shareholders. Such reviews are common and rarely block a deal, but they can delay closing or pressure for a higher price, adding a small amount of uncertainty.

    It is the main counterweight to the buyout, showing the deal is not entirely risk-free for shareholders.

  • AbbVie's strong results support deal closing AbbVie reported 10.2% revenue growth and raised its profit outlook, while noting the Apogee purchase will slightly reduce its 2026 earnings. A healthy buyer with growing cash flow makes it more likely the all-cash deal closes on the agreed terms.

    AbbVie's financial strength is the practical backing for the $135.11 cash payment Apogee holders expect.

July 2026
▲3▼1

AbbVie's $10.9B Apogee Buy Moves Toward Close, Funding Debt

  • AbbVie to acquire Apogee for $10.9B cash AbbVie agreed to buy Apogee for $10.9 billion in cash, a premium to the market price. This is the main reason APGE trades near the deal value. The deal is expected to close in the third quarter, so APGE's price is now tied to deal completion, not independent drug news.

    This is the core event that determines APGE's price now.

  • AbbVie funds deal with debt, preserving dividend AbbVie will pay for Apogee entirely with debt, not cash on hand, so its dividend remains safe. This reduces any risk that financing problems could delay or derail the deal. For APGE holders, it means the agreed cash price is more likely to be paid as planned.

    Shows the deal is well-financed, lowering risk to APGE's takeover price.

  • AbbVie's strong immunology growth supports deal rationale AbbVie raised its 2026 revenue outlook to $67.6 billion and said its Skyrizi and Rinvoq drugs are growing fast. Apogee's eczema drug zumilokibart fits into that immunology pipeline. Strong buyer performance makes it more likely AbbVie completes the purchase and invests in the asset.

    Confirms the buyer's health and strategic need for Apogee, supporting deal certainty.

  • Deal dilutes AbbVie EPS, but APGE unaffected AbbVie lowered its 2026 earnings guidance by about 14 cents per share because of the Apogee acquisition, and its stock dipped. This is a cost to AbbVie, not Apogee. APGE's agreed cash price does not change, so this does not hurt APGE's takeover value.

    Addresses the main negative headline and clarifies it does not reduce APGE's deal price.

▲3▼1

AbbVie's $10.9B Apogee Buy Moves Toward Close, Funding Debt

  • AbbVie to acquire Apogee for $10.9B cash AbbVie agreed to buy Apogee for $10.9 billion in cash, a premium to the market price. This is the main reason APGE trades near the deal value. The deal is expected to close in the third quarter, so APGE's price is now tied to deal completion, not independent drug news.

    This is the core event that determines APGE's price now.

  • AbbVie funds deal with debt, preserving dividend AbbVie will pay for Apogee entirely with debt, not cash on hand, so its dividend remains safe. This reduces any risk that financing problems could delay or derail the deal. For APGE holders, it means the agreed cash price is more likely to be paid as planned.

    Shows the deal is well-financed, lowering risk to APGE's takeover price.

  • AbbVie's strong immunology growth supports deal rationale AbbVie raised its 2026 revenue outlook to $67.6 billion and said its Skyrizi and Rinvoq drugs are growing fast. Apogee's eczema drug zumilokibart fits into that immunology pipeline. Strong buyer performance makes it more likely AbbVie completes the purchase and invests in the asset.

    Confirms the buyer's health and strategic need for Apogee, supporting deal certainty.

  • Deal dilutes AbbVie EPS, but APGE unaffected AbbVie lowered its 2026 earnings guidance by about 14 cents per share because of the Apogee acquisition, and its stock dipped. This is a cost to AbbVie, not Apogee. APGE's agreed cash price does not change, so this does not hurt APGE's takeover value.

    Addresses the main negative headline and clarifies it does not reduce APGE's deal price.

Q2 2026
▲2

AbbVie's $10.9B buyout of Apogee lifts APGE near offer price

  • AbbVie acquisition at $135.11/share AbbVie agreed to buy Apogee for $10.9 billion in cash, or $135.11 per share, a 49–60% premium. The deal centers on Apogee's phase-two eczema drug zumilokibart, which analysts think could rival Dupixent.

    This is the main event that drove APGE's price during the period.

  • All-cash deal funded from AbbVie's cash flow AbbVie can pay for the all-cash deal from its operating cash flow, making the payout more certain for Apogee shareholders. However, the deal won't add to AbbVie's earnings until 2032.

    Explains why the offer price is credible and supports APGE's price near the offer.

  • Board investigation adds deal risk A board investigation by Brodsky & Smith into whether Apogee ran a fair sales process adds risk. A lawsuit or higher bid could delay or alter the $135.11 payout, creating uncertainty for shareholders.

    This is a real counterweight that could affect whether the deal closes as planned.

  • APGE trades near offer price, upside capped APGE trades near the offer price, capping further upside unless a competing bid emerges. The stock is unlikely to rise much above $135.11 without a rival offer.

    Describes the current trading dynamic and limits to further gains.

June 2026
▲2

AbbVie's $10.9B buyout of Apogee lifts APGE near offer price

  • AbbVie acquisition at $135.11/share AbbVie agreed to buy Apogee for $10.9 billion in cash, or $135.11 per share, a 49–60% premium. The deal centers on Apogee's phase-two eczema drug zumilokibart, which analysts think could rival Dupixent.

    This is the main event that drove APGE's price during the period.

  • All-cash deal funded from AbbVie's cash flow AbbVie can pay for the all-cash deal from its operating cash flow, making the payout more certain for Apogee shareholders. However, the deal won't add to AbbVie's earnings until 2032.

    Explains why the offer price is credible and supports APGE's price near the offer.

  • Board investigation adds deal risk A board investigation by Brodsky & Smith into whether Apogee ran a fair sales process adds risk. A lawsuit or higher bid could delay or alter the $135.11 payout, creating uncertainty for shareholders.

    This is a real counterweight that could affect whether the deal closes as planned.

  • APGE trades near offer price, upside capped APGE trades near the offer price, capping further upside unless a competing bid emerges. The stock is unlikely to rise much above $135.11 without a rival offer.

    Describes the current trading dynamic and limits to further gains.

▼1

Apogee's $135.11 AbbVie buyout holds, but board probe adds risk

  • Board investigation could delay or reduce deal payout Brodsky & Smith is investigating whether Apogee's board ran a fair sales process and got a fair price. If the probe leads to a lawsuit or a higher bid, the $135.11 cash payout could be delayed or changed, which is a risk for shareholders waiting for the deal to close.

    This is the only new event that could actually change the deal terms or timing, directly affecting APGE's price.

▲3

AbbVie's $10.9B cash buyout locks in a big premium for Apogee

  • AbbVie agrees to buy Apogee for $10.9 billion in cash AbbVie will pay $135.11 per share in cash, a roughly 49-60% premium to Apogee's prior close. That fixed price is now the main driver: APGE trades near it, and the deal caps further upside unless a higher bid emerges.

    This is the definitive event that sets APGE's price and explains the period's move.

  • Apogee's eczema drug zumilokibart is the strategic prize The lead drug, in phase two testing, could rival blockbuster Dupixent for atopic dermatitis. Analysts say strong data and scarce immunology assets justify the premium, supporting the deal price and making a rival bid possible.

    It explains why AbbVie is paying up and why the buyout price is credible.

  • AbbVie can fund the all-cash deal without new debt AbbVie will use operating cash flow, so the buyout is not at risk from financing. That makes the $135.11 cash payout more certain for Apogee holders, though AbbVie says the deal won't add to earnings until 2032.

    Financing certainty supports the deal closing and the cash value to APGE holders.